Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a prospective study, sixty-five histologically verified Swedish cases of Hodgkin's disease were HL-A typed. The antigen frequencies in the patient group did not deviate from a group of normal controls. The frequency of HL-A8 was slightly increased in patients over 40 years (P less than 0.05). HL-A12 was markedly increased in patients below 40 years with a favourable histopathology (P less than 0.001). No association between sex or clinical stage and distribution of HL-A phenotypes was observed. The number of T-lymphocytes in blood and the spontaneous DNA synthesis and DNA synthesis induced by concanavalin A, pokeweed mitogen, phytohemagglutinin and PPD antigen in blood lymphocytes in vitro were determined in 60 patients. A significant increase of HL-A28 was noted in patients with advanced disease (P less than 0.01) and in patients responding poorly to PPD (P less than 0.001) and PWM (P less than 0.01). No correlation between HL-A antigen distribution and T-lymphocyte counts was observed.
 ...
PMID:A prospective study of HL-A antigen phenotypes and lymphocyte abnormalities in Hodgkin's disease. 108 76

The study comprises 38 unselected and untreated patients with Hodgkin's disease (HD) and 23 healthy persons. Highly purified blood lymphocytes were analyzed for cells forming rosettes with sheep red blood cells (T lymphocytes), and lymphocytes bearing surface immunoglobulin (B lymphocytes) and/or carrying receptors for complement. Their DNA synthesis, spontaneously, or after activation with mitogens (phytohemagglutinin, concanavallin A, poke weed mitogen) and purified protein derivative (PPD) was measured. Delayed skin hypersensitivity to PPD and mumps antigen was studied. Most HD patients had low numbers of T lymphocytes (50% of the cases below normal range) while the mean B-lymphocyte level was normal but with a greater variation than in the control group. Lymphocytes from most patients were poorly stimulated by T-cell mitogens. Two-thirds of the patients and one healthy control had negative skin reaction to 2 TU PPD and the DNA synthesis of their lymphocytes after activation with PPD was low. Large lymphoid cells (greater than 9-mm diameter) were commonly present in HD blood and the spontaneous DNA synthesis was high, particularly in lymphocytes from stage B patients. The percentage of T lymphocytes and the stimulation of lymphocytes by T-cell mitogens or by PPD, a T-lymphocyte function, did not correlate and each test only detected defects in about half the cases. Simultaneous application of all tests revealed abnormalities of blood T lymphocytes in 33 out of 38 patients. Although the defects were usually more pronounced in patients with advanced disease, the impairment of T lymphocytes and their functions is present in all stages of Hodgkin's disease.
 ...
PMID:Lymphocyte abnormalities in untreated patients with Hodgkin's disease. 108 95

There is clinical evidence that the immune response can increase or decrease cancer growth. 1) Cancer is increased in congenital immune deficiency states and in those given immuno-suppressants after renal transplantation; 2) there is a correlation between mononuclear cell infiltration and prognosis; 3) spontaneous regression occurs occasionally on an immunologic basis; 4) cancer specific antigens and antibodies can be demonstrated, and 5) immunotherapy can cause tumor regression. The cells that are responsible for the immune response are 1) families of thymic-derived lymphocytes, or T-cells, ("memory," "effector", "helper" or "suppressor" T-cells), and 2) bursal-derived lymphocytes, or B-cells, which on specific sensitization become either plasma cells that produce cytotoxic or blocking antibody or macrophages (A-cells) that process antigen, and may become "armed" with cytophilic antibody. The main effect of local radiotherapy is to destroy certain families of radiosensitive lymphocytes in the afferent, central and efferent components of the immune response. In Hodgkin's disease, extended field radiotherapy causes a prolonged decrease in the number of lymphocytes in the peripheral blood and a decrease in function of the cells, as determined by RNA and DNA synthesis after culture with mitogen, phytohemagglutinin. There is no correlation, however, with the values after treatment and recurrence of the disease. The effect of local radiotherapy to large volumes of tissues, on the incidence of new primary cancers, is uncertain but the majority of reports show that it is no effect.
 ...
PMID:Immunologic considerations of large volume radiotherapy. 108 53

The effectiveness of synchronization therapy was tested on 88 patients who had already undergone some form of treatment for lymphogranulomatosis (stage III B and IV), generalized reticulum cell sarcoma or lymphosarcoma. This therapeutical concept is based on a partial synchronic increase in tumor cells induced by noncytocidal doses of vincristine, followed by cytostatic or cytocidal treatment with cyclophosphamide during DNA synthesis of the partially synchronized tumor cells. The therapeutic plan is similar to a single-agent therapy. In lymphogranulomatosis, complete remission could be achieved in 14 out of 19 cases (stage III B) and in 9 out of 24 cases (stage IV). The mean remission period during an orally administered cytostatic maintenance therapy was 15 1/2 months. The highest rate of remission was found in the mixed cell type of granulomas (23 out of 24 patients). In the non-Hodgkin's lymphomas, complete remission was achieved in 13 out of 30 cases (lymphosarcoma) and in 19 out of 15 cases (reticulum cell sarcoma). The mean remission period for orally administered cytostatic maintenance therapy was 16 months for lymphosarcoma and 11 1/2 months for reticulum cell sarcoma. These therapeutic results are comparable to those achieved by very effective schemes of combination chemotherapy but the toxic side-effects of synchronization therapy are considerably lower.
 ...
PMID:[Results of the synchronization therapy with vincristine and cyclophosphamide in lymphogranulomatosis, reticulum cell sarcoma and lymphosarcoma. A phase II study (author's transl)]. 109 86

Autotransfusions of the DNA synthesizing blood cells from 2-2.5 liters of blood, labelled in vitro with 3H-thymidine, were performed in 2 patients with Hodgkin's disease. The fate of the labelled lymphoid cells was followed up for 5 min to 60 h in the circulating blood and occasionally in the lymph node tissue. The data indicate that 1) circulating DNA synthesizing large lymphoid cells leave the blood in less than 2 h; 2) they produce by mitosis large and medium sized lymphocytes, which mainly appear in blood and lymph nodes and 3) their generation time, in agreement with other estimates, is about 25 h.
 ...
PMID:On the fate of DNA synthesizing lymphoid blood cells in Hodgkin's disease. 112 44

The authors have followed the excretion of pyrimidine doexyribonucleosides in the urine of patients with generalized stages of Hodgkin's disease. They proved an increased excretion of deoxyuridine and thymidine in these patients compared to healthy persons. In the course of 14-days of combined chemotherapy a statistically significant increase in the excretion of DNA catabolites followed was found.
 ...
PMID:Urine excretion of nucleosides in Hodgkin's disease treated by combined chemotherapy. 113 91

The study of the possibilities of new DNA synthesis by the Sternberg-Reed cells of Hodgkin disease was done with tritated thymidine and autoradiography. The results showed that after incubation pulses of 30 and 60 minutes cells with lobulated nucleus, binucleated and trinucleated cells, identifiable to the diagnostic Sternberg-Reed cells, had possibilities of new DNA synthesis. This points to a more dynamic interpretation of this cell that was considered without chances of cnromosome replication.
 ...
PMID:In vitro incorporation of tritiated thymidine by the Sternberg-Reed cells in Hodgkin disease. 116 Nov 14

Interferons produced by recombinant DNA technology began phase I trials little more than a decade ago. Today interferon alfa-2 is a mainstay in the treatment of hairy cell leukemia, and has demonstrated benefit in the more common chronic myelogenous leukemia. Interferon alfa-2 also has activity in other hematologic malignancies, including indolent non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, T-cell lymphoma, and multiple myeloma, and in solid tumors such as disseminated melanoma, renal cell carcinoma, Kaposi's sarcoma, endocrine pancreatic tumors, and malignant carcinoid tumors. Interferon alfa, beta, and gamma remain under investigation to define potential roles in ovarian, breast, bladder, and cervical carcinomas and gliomas. The greatest value of the interferons will be in prolonging the disease-free interval when used in combination with other treatment modalities, including surgery, radiation, chemotherapy, and other biologic agents.
 ...
PMID:Current status of interferons in the treatment of cancer. 128 Jan 53

In the literature EBV is considered a possible etiologic factor for Hodgkin's disease (HD). We investigated 187 cases of HD for the presence of Epstein Barr virus using the polymerase chain reaction (PCR) technique on formalin fixed, paraffin embedded lymph node tissue to clarify the clinical importance of the incidence of this genome. The 187 cases included all subtypes. 66 cases (35.2%) were positive for EBV DNA. The statistical analysis of follow-up data from 130 patients revealed no influence of EBV DNA on survival time. In our investigation detection of EBV DNA by PCR showed no prognostic relevance for patients with HD.
 ...
PMID:[Influence of Epstein-Barr virus genome on patient survival in Hodgkin's disease]. 128 53

Studies demonstrating Epstein-Barr virus (EBV) DNA in Hodgkin's disease (HD) provide little information about the EBV-status in the lymphocyte predominant subtype (nodular paragranuloma) which is due to the small number of cases investigated. Therefore we studied 99 typical cases of nodular paragranuloma for the presence of EBV-DNA using the polymerase chain reaction (PCR) technique. Genomic DNA was amplifiable in 71 cases; 29 cases (= 40%) were positive for EBV-DNA (EBNA-1). In situ hybridization revealed EBV-RNA (EBER-1) in L&H cells and in a few lymphocytes. PCR results were correlated to clinical follow-up data and did not show any statistically significant relationship between EBV positivity and survival of the patients.
 ...
PMID:[Nodular paragranuloma and Epstein-Barr virus: frequency of EBV DNA and clinical relevance]. 128 54


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>